Williams Paul Anthony sold $20K of EBS

Williams Paul Anthony (SVP, Products Business) sold 3,000 shares of Emergent BioSolutions Inc. (EBS) at $6.53 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Williams Paul Anthony
Published Oct 5, 2026, 1:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EBS
Neutral
high confidence
Mentioned
$EBS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EBSNeutralLow
01

Why it matters

The transaction is modest and pre‑arranged, likely causing negligible price movement.

02

Market read

A small insider sell with limited market impact; primarily of interest to compliance and monitoring teams.

03

What to watch

The sale is pre‑arranged under a 10b5‑1 plan, reducing informational value.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-10-01

Background

Form 4 filings disclose insider transactions; this filing reports a routine sale by a senior officer.

Company-level read

Ticker impact

$EBSNeutralHigh confidence
Context

SVP sold 3,000 shares for $19,590 via a 10b5-1 plan, reducing his stake to 156,098 shares.

Expected impact

likely slight pressure as market prices in the insider sale

Evidence & confidence

The sale is small relative to float and disclosed via a pre‑arranged plan, limiting surprise.

Market effects

Minimal impact on biotech sector; typical insider sale.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

Some traders view any insider sell as a red flag, potentially signaling upcoming issues.

Key entities

  • Williams Paul Anthony

    SVP, Products Business at Emergent BioSolutions

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)